A new biotechnology for articular cartilage repair: subchondral implantation of a composite of interconnected porous hydroxyapatite, synthetic polymer (PLA-PEG), and bone morphogenetic protein-2 (rhBMP-2)

Osteoarthritis Cartilage. 2005 May;13(5):405-17. doi: 10.1016/j.joca.2004.12.014.

Abstract

Objective: Articular cartilage repair remains a major obstacle in tissue engineering. We recently developed a novel tool for articular cartilage repair, consisting of a triple composite of an interconnected porous hydroxyapatite (IP-CHA), recombinant human bone morphogenetic protein-2 (rhBMP-2), and a synthetic biodegradable polymer [poly-d,l-lactic acid/polyethylene glycol (PLA-PEG)] as a carrier for rhBMP-2. In the present study, we evaluated the capacity of the triple composite to induce the regeneration of articular cartilage.

Methods: Full-thickness cartilage defects were created in the trochlear groove of 52 New Zealand White rabbits. Sixteen defects were filled with the bone morphogenetic protein (BMP)/PLA-PEG/IP-CHA composite (group I), 12 with PLA-PEG/IP-CHA (group II), 12 with IP-CHA alone (group III), and 12 were left empty (group IV). The animals were killed 1, 3, and 6 weeks after surgery, and the gross appearance of the defect sites was assessed. The harvested tissues were examined radiographically and histologically.

Results: One week after implantation with the BMP/PLA-PEG/IP-CHA composite (group I), vigorous repair had occurred in the subchondral defect. It contained an agglomeration of mesenchymal cells which had migrated from the surrounding bone marrow either directly, or indirectly via the interconnecting pores of the IP-CHA scaffold. At 6 weeks, these defects were completely repaired. The regenerated cartilage manifested a hyaline-like appearance, with a mature matrix and a columnar organization of chondrocytes.

Conclusions: The triple composite of rhBMP-2, PLA-PEG, and IP-CHA promotes the repair of full-thickness articular cartilage defects within as short a period as 3 weeks in the rabbit model. Hence, this novel cell-free implant biotechnology could mark a new development in the field of articular cartilage repair.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biocompatible Materials / administration & dosage
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins / administration & dosage*
  • Bone Regeneration / drug effects
  • Bone Regeneration / physiology
  • Cartilage Diseases / drug therapy*
  • Cartilage Diseases / pathology
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / pathology*
  • Chondrocytes / drug effects
  • Chondrocytes / physiology
  • Drug Carriers
  • Durapatite / administration & dosage*
  • Lactates / administration & dosage*
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / physiology
  • Microscopy, Electron, Scanning / methods
  • Polyethylene Glycols / administration & dosage*
  • Rabbits
  • Transforming Growth Factor beta / administration & dosage*
  • Wound Healing / drug effects
  • Wound Healing / physiology

Substances

  • BMP2 protein, human
  • Biocompatible Materials
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins
  • Drug Carriers
  • Lactates
  • Transforming Growth Factor beta
  • poly(lactic acid-ethylene glycol)
  • Polyethylene Glycols
  • Durapatite